What Is Foundayo (Orforglipron)?

What is Foundayo?

Foundayo explained: it is the brand name for orforglipron, a new weight loss treatment developed by Eli Lilly.

Most GLP-1 weight loss medications are peptides. The stomach breaks them down the same way it digests food. GLP-1 medications typically come as injections to bypass the gut. 

One oral GLP-1 already exists – the Wegovy daily pill. But because it is still a peptide, it comes with strict dosing rules to stop the stomach from digesting it.

Foundayo (orforglipron) is a non-peptide small-molecule drug, closer to a conventional tablet. Your stomach does not break it down the same way as a peptide. You can take the Foundayo tablet at any time of day, with or without food, and with no water restrictions or fasting window.

How does Foundayo work?

Every time you eat, your gut releases a hormone called GLP-1 (glucagon-like peptide-1). Several things happen as a result: your brain receives a signal that you are full, and food moves through your stomach more slowly. Natural GLP-1 breaks down within minutes, but Foundayo keeps that signalling active for longer. This helps reduce hunger across the day.

Weight loss is not always the first thing people notice. The constant background thinking about food becomes quieter – cravings ease, and overcoming snacking becomes less of a challenge. Meals are more filling than before, and portions naturally shrink. 

People come to realise they are eating less without actively planning to. No calorie counting or portion restriction needed. We will always recommend eating a healthy, balanced diet while losing weight to ensure you are receiving adequate nutrition.

How Foundayo works on appetite involves the same brain pathways as other GLP-1 medications. For some, appetite changes are seen within the first few weeks. Others do not notice much until reaching higher doses. Weight loss tends to build gradually over the first few months as the dose increases.

Who is Foundayo for?

The FDA (US Food and Drug Administration) approved Foundayo medication on 1st April 2026 for adults aged 18 and over. To be suitable for treatment, you need a BMI of 30 or above. Alternatively, you can qualify with a BMI of 27 or above if you also have a weight-related co-morbidity, such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnoea.

Foundayo is not yet available in the UK. NHS approval depends on two steps: 

1. MHRA (Medicines and Healthcare products Regulatory Agency) approval first 
2. NICE (National Institute for Health and Care Excellence) review for NHS funding

MHRA approval is anticipated for late 2026 or early 2027. Private prescriptions can begin at this point. We will update you once Foundayo is available.

What is Foundayo used for?

Foundayo is designed for longer-term weight management – not a quick fix. Most people lose weight gradually over several months. You are likely to see better results if you also make changes to your diet and activity levels. Those habits matter long term: weight regain is common after stopping GLP-1 treatment without them in place.

Eli Lilly is also seeking approval for orforglipron as a type 2 diabetes treatment, but that is still in the pipeline. Weight management is currently its only licensed use.

Who should not take Foundayo?

Foundayo carries the same boxed thyroid warning as all GLP-1 medications. This is the strongest safety warning the FDA issues. Animal studies involving other GLP-1 drugs found thyroid tumours, although this has not been seen in humans. Because of this warning, you must not take Foundayo if you have:

• a personal or family history of medullary thyroid cancer
• a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

If you have severe liver problems, Foundayo is not suitable for you. Mild or moderate liver problems are not necessarily a barrier, but your prescriber should assess this. 

Pregnancy, trying to conceive and breastfeeding all rule out Foundayo. The contraceptive pill can also become less reliable while taking it. Use condoms or a diaphragm alongside the pill for the first 30 days and after each dose increase. Alternatives like the implant, depot injection, or coil are worth discussing with your local sexual health clinic. 

Stop taking Foundayo immediately if you become pregnant, and let your GP and our clinical team know.

How effective is Foundayo for weight loss?

Average weight loss on the highest Foundayo dose is around 11% over 72 weeks. If you’re starting at 100 kg, that is a roughly 11 kg loss. On the lowest maintenance dose, it is closer to 7.5%.

These figures come from the ATTAIN-1 clinical trial. Over 3,000 adults with obesity took either Foundayo or a placebo (an inactive treatment), along with a healthy, balanced diet and increased physical activity. 

Over half the people on the highest dose lost at least 10% of their starting body weight. About four in ten lost 15% or more. The placebo group lost about 2%.

Injectable GLP-1 treatments tend to produce more weight loss in trials. Wegovy’s main trial showed around 15%, Mounjaro around 21%. Direct comparison of the results should take into consideration that the studies were designed differently, and different patients were enrolled.

How is Foundayo different from other GLP-1 treatments?

All GLP-1 weight-loss treatment currently available in the UK is in injection form. Most are administered weekly, and injected into the stomach, thigh, or upper arm. They need refrigeration, so travel requires planning, cool bags and ice packs. Needle anxiety puts some people off starting, and the ongoing routine pushes others to stop early.

Oral Wegovy is the only other GLP-1 tablet option. Currently limited to the US, it too awaits UK approval. It tends to produce greater weight loss in trials. But it comes with strict dosing conditions: empty stomach, no more than 120 ml of water, then a 30-minute wait before eating or drinking. 

Some people are comfortable with the dosing rules. Others find it hard and as a result stop following the routine after a while.

Foundayo has none of those rules. You take one tablet a day, whenever suits you, with or without food. Store at room temperature, in the original packaging. For people who have avoided injectables or struggled with oral Wegovy’s dosing conditions, the convenience of Foundayo may matter more than a higher rate of weight loss. 

What are the common side effects of Foundayo?

Nausea is the most common side effect. Roughly three in ten people in trials experienced it, depending on the dose. Most side effects of Foundayo are gut-related, simply because of how it works. If you have been on another GLP-1 before, you will likely recognise them.

Constipation, diarrhoea, and vomiting were each reported in about one in four people at the highest dose. Stomach pain and indigestion were less common. People in the trials also reported headache, bloating, tiredness, burping, acid reflux, wind, and hair loss. 

In the trials, most side effects were mild to moderate. Up to one in 10 trial participants had to stop taking Foundayo because of these symptoms.

The Foundayo dosage starts at 0.8 mg and goes up every 30 days. Each step up can temporarily bring back nausea or stomach discomfort that had eased at the previous dose. For many people, it settles within a week or two. Prescribers often slow dose increases or reduce dose if symptoms are difficult to manage.

Serious side effects are less common but can happen. They include pancreatitis (inflammation of the pancreas), gallbladder problems, kidney injury linked to dehydration, and serious allergic reactions. Severe or persistent stomach pain is a reason to stop taking Foundayo and see your GP urgently or go to A&E.

When should I see a doctor?

Call 999 if you develop swelling of your face, lips, or throat, have difficulty breathing, or feel tightness in your chest. This may indicate a severe allergic reaction and needs emergency treatment.

Stop taking Foundayo and go to A&E if you experience:

• Severe stomach pain that spreads to your back, with or without vomiting, this can indicate pancreatitis.
• Yellowing of your skin or eyes, fever, or clay-coloured stools. These may be signs of a gallbladder problem.
• Nausea, vomiting, or diarrhoea that does not let up and leaves you unable to keep fluids down for more than 24 hours. Prolonged dehydration can lead to kidney injury.

If you notice a new lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath, these can be signs of a thyroid problem. 

Changes in vision may be a sign of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). This can lead to permanent damage if untreated.

If you experience either of these effects, book a GP appointment immediately. 

NHS 111 can help if you are unsure whether your symptoms need urgent attention or can wait for a GP appointment. 

If your side effects feel manageable but are not improving after two weeks, speak to our clinical team. We can review your dose and adjust your treatment plan.

Frequently asked questions

Is Foundayo the same drug as orforglipron?

Yes. Foundayo is the brand name, orforglipron is the generic name of the Foundayo drug. Meaning it has the same active ingredient.

What is orforglipron used for?

Weight management only, at the moment. Eli Lilly is seeking approval for type 2 diabetes separately, but no country has granted that yet. In the US, orforglipron is approved for adults with obesity or who are overweight alongside a weight-related health condition.

What is orforglipron?

Orforglipron explained simply: it is a small-molecule drug that copies the function of a gut hormone called GLP-1. It reduces appetite and helps you feel full for longer. Unlike other GLP-1 drugs, your stomach does not break it down, so you can take it as a tablet rather than an injection. 

What medical conditions qualify me for Foundayo?

You may be suitable for treatment if your BMI is 30 or above. If your BMI is 27 or above, you would also need at least one weight-related medical condition. This can include type 2 diabetes, high blood pressure, high cholesterol, or sleep apnoea. Your prescriber can confirm whether this treatment is right for you.

Key takeaways

• Foundayo (orforglipron) is the first non-peptide oral GLP-1 approved for weight management in the US. The FDA approved Foundayo in April 2026.
• You do not need to take Foundayo around fasting windows or water limits.
• In the ATTAIN-1 trial, people taking the highest dose lost around 11% of body weight over 72 weeks.
• Not yet available in the UK. MHRA approval is pending, with private access possibly following in late 2026 or 2027. NHS availability would depend on a separate NICE review.
• Nausea and stomach symptoms are most common early in treatment, especially after dose increases.

References

FDA Approves First New Molecular Entity Under National Priority Voucher Program, US Food and Drug Administration, 2026 [Accessed 11 May 2026].

Foundayo (orforglipron) Prescribing Information, U.S. Food and Drug Administration, 2026 [Accessed 11 May 2026].

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), New England Journal of Medicine, 2025 [Accessed 11 May 2026].

FDA Approves Lilly’s Foundayo (Orforglipron), Eli Lilly and Company, 2026 [Accessed 11 May 2026].

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron, Diabetes Therapy, 2024 [Accessed 11 May 2026].

Wegovy 2.4 mg Summary of Product Characteristics (SmPC), EMC / Novo Nordisk, 2026 [Accessed 11 May 2026].

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine, 2021 [Accessed 11 May 2026].

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022 [Accessed 11 May 2026].

Lilly’s Oral GLP-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials, Eli Lilly and Company, 2025 [Accessed 11 May 2026]. 

Authorship